H
Hariharan Easwaran
Researcher at Johns Hopkins University
Publications - 59
Citations - 5062
Hariharan Easwaran is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: DNA methylation & Epigenetics. The author has an hindex of 30, co-authored 50 publications receiving 4139 citations. Previous affiliations of Hariharan Easwaran include Max Delbrück Center for Molecular Medicine & Ghent University.
Papers
More filters
Journal ArticleDOI
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
TL;DR: The possible role of epigenetic abnormalities as well as genetic alterations in such dynamics and in the creation of cellular heterogeneity in cancers of all types are discussed.
Journal ArticleDOI
Oxidative Damage Targets Complexes Containing DNA Methyltransferases, SIRT1, and Polycomb Members to Promoter CpG Islands
Heather M. O'Hagan,Wei Wang,Subhojit Sen,Christina E. DeStefano Shields,Stella S. Lee,Yang W. Zhang,Eriko G. Clements,Yi Cai,Leander Van Neste,Hariharan Easwaran,Robert A. Casero,Robert A. Casero,Cynthia L. Sears,Stephen B. Baylin +13 more
TL;DR: It is demonstrated that inducing cellular oxidative stress by hydrogen peroxide treatment recruits DNA methyltransferase 1 (DNMT1) to damaged chromatin, forming a silencing complex that may explain cancer-specific aberrant DNA methylation and transcriptional silencing.
Journal ArticleDOI
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.
Huili Li,Katherine B. Chiappinelli,Angela A. Guzzetta,Hariharan Easwaran,Ray Whay Chiu Yen,Rajita Vatapalli,Michael J. Topper,Jianjun Luo,Roisin M. Connolly,Nilofer S. Azad,Vered Stearns,Drew M. Pardoll,Nancy E. Davidson,Peter A. Jones,Dennis J. Slamon,Stephen B. Baylin,Cynthia A. Zahnow,Nita Ahuja +17 more
TL;DR: Results point to a broad immune stimulatory role for DNA demethylating drugs in multiple cancers, particularly in breast and colorectal cancers.
Journal ArticleDOI
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine
John Wrangle,Wei Wang,Alexander Koch,Hariharan Easwaran,Helai P. Mohammad,Frank P. Vendetti,Wim Vancriekinge,Timothy Demeyer,Zhengzong Du,Princy Parsana,Kristen Rodgers,Ray-Whay Chiu Yen,Cynthia A. Zahnow,Janis M. Taube,Julie R. Brahmer,Scott S. Tykodi,Keith Easton,Richard D. Carvajal,Peter A. Jones,Peter W. Laird,Daniel J. Weisenberger,Salina Tsai,Rosalyn A. Juergens,Suzanne L. Topalian,Charles M. Rudin,Malcolm V. Brock,Drew M. Pardoll,Stephen B. Baylin +27 more
TL;DR: It is hypothesize that epigenetic therapy combined with blockade of immune checkpoints – in particular the PD-1/PD-L1 pathway – may augment response of NSCLC by shifting the balance between immune activation and immune inhibition, particularly in a subset ofNSCLC with low expression of AZA-induced immune genes.
Journal ArticleDOI
A DNA hypermethylation module for the stem/progenitor cell signature of cancer
Hariharan Easwaran,Sarah E. Johnstone,Leander Van Neste,Joyce E. Ohm,Tim Mosbruger,Qiuju Wang,Martin J. Aryee,Patrick Joyce,Nita Ahuja,Daniel J. Weisenberger,Eric A. Collisson,Jingchun Zhu,Srinivasan Yegnasubramanian,William Matsui,Stephen B. Baylin +14 more
TL;DR: Evidence is provided that DNA hypermethylation preferentially targets the subset of PcG genes that are developmental regulators, and this may contribute to the stem-like state of cancer.